Type 2 Diabetes
Introduction to type 2 diabetes
The prevalence of type 2 diabetes is growing at an alarming rate with past forecasts being exceeded years before predicted. In 2017, over 420 million people were living with diabetes and this number is expected to continue rising with the increasing levels of obesity seen in populations around the world.
However, effective treatment alternatives are available to reduce the burden and manage the risk of complications of type 2 diabetes. Explore the type 2 diabetes section for expert insights into the future of diabetes, the need to address clinical inertia, and view a range of Novartis-sponsored webinar topics.
In this section, you can learn about the epidemiology of type 2 diabetes and its links to obesity as well as watch physician and patient thoughts on the future of diabetes.
You can also view a presentation by Dr Edwin B Villhauer who led the team that discovered the first DPP-4 inhibitor, vildagliptin, get a concise view of the ESC guidelines on renin-angiotensin system (RAS) blockers as well as read four recent publications that marked the recent 10th anniversary of the vildagliptin.
Time2DoMore™ in diabetes
Discover what is meant by clinical inertia, its impact on type 2 diabetes management as well as understanding more about the Time2DoMoreTM initiative.
What is the Time2DoMoreTM initative and how can it help overcome treatment inertia?
The Time2DoMoreTM in diabetes initiative sought to understand why we are not able to reach glycaemic goals in type 2 diabetes patients and what are the barriers to optimised diabetes care. By speaking to 337 physicians and 652 patients from around the world, the initiative gained a valuable insight into the challenges faced by patients with type 2 diabetes and their doctors (Strain et al., 2014a).
The following recordings from Novartis-sponsored scientific webinars provide important insights into the management of type 2 diabetes The webinar on this site is intended for non-promotional scientific purposes only and has been independently developed by the speakers.
Type 2 Diabetes References
Ahmad N, Alfaris N. VLCD for weight loss and remission of type 2 diabetes? Lancet. 2018;392(10155):1306–7.
Diabetes Atlas Committee. Diabetes Atlas. 2nd ed. Belgium: International Diabetes Federation; 2003.
Diabetes Atlas Committee. Diabetes Atlas. 8th ed. International Diabetes Federation; 2017.
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007;356:213–21.
Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017;15:131.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51.
World Health Organization. Noncommunicable diseases fact sheet. 2017a. Available at www.who.int/mediacentre/factsheets/fs355/en/ (accessed March 2018).
World Health Organization. Diabetes fact sheet. 2017b. Available at www.who.int/mediacentre/factsheets/fs312/en/ (accessed March 2018).
World Health Organization. Obesity and overweight fact sheet. 2018. Available at www.who.int/mediacentre/factsheets/fs311/en/ (accessed March 2018).
Strain D. Time to do more for diabetes: Clinical inertia and how to beat it. Diabetes Voice. 2014;59:36–9.
Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: Is there time to do more in type 2 diabetes? Diabetes Ther. 2014b:5:347–54.
Strain ED, Cos X, Hirst M, Vencio S, Mohan V, Vokó Z, et al. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014a;105(3):302–12.
The videos on this site have been developed independently by the speaker and intended for non-promotional scientific purposes only. The views presented are that of the presenter and not necessarily those of the industry sponsor, Novartis Pharma AG. Time2DoMore is a trademark owned by Novartis Pharma AG. Following codes supersede any other material reference number appearing on the assets: GLEM/GAL/0072, 75, 79, 84, 99.
Date of preparation December 2019 GLEM/GAL/0099.